EGFR and non-small cell lung carcinoma: Gefitinib as the first-generation EGFR-TKI has markedly prolonged the overall survival of NSCLC patients; however, drug resistance has been eventually harboured leading to the ultimate failure of clinical treatments (Hirsch et al., 2016).